A Phase 3 interventional study of RSVpreF in Respiratory Syncytial Virus (RSV), sponsored by Pfizer. Completed at 5 sites in Japan. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.
The study is seeking participants who are:
It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.
This is a Phase 3, multicenter, single-arm, open-label study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to 59 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions in Japan.
Approximately 130 participants 18 to 59 years of age considered at high risk of RSV disease due to certain chronic medical conditions will be enrolled to receive RSVpreF.
The total duration of trial participation for each participant will be 2 months.
After screening and confirmation of eligibility, a prevaccination blood sample will be collected for immunogenicity assessments and a single dose of study intervention (RSVpreF) will be administered.
Participants will report daily reactogenicity data using an electronic device for 7-days or until resolution.
Participants will return approximately 1 month later for a follow-up blood draw for immunogenicity assessments and collection of safety information.
A telephone follow-up visit will be conducted approximately 2 months after vaccination to collect safety information.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Please refer to the study contact for further eligibility details.
RSV Vaccine
Biological: RSVpreF
RSV Vaccine
Percentage of participants reporting prompted local reactions within 7 days following investigational product administration
Describe prompted local reactions following investigational product administration
Time frame: Day 7
Percentage of participants reporting prompted systemic events within 7 days following investigational product administration
Describe prompted systemic events following investigational product administration
Time frame: Day 7
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
Describe AEs occurring through 1 month following administration of investigational product
Time frame: 1 month after vaccination
Percentage of participants reporting serious adverse events (SAEs) throughout the study
Describe SAEs through 2 months following administration of investigational product
Time frame: 2 months after vaccination
Geometric Mean Titer (GMT) ratio (GMR) , estimated by the ratio of the GMTs for RSV subgroup A (RSV A) and RSV subgroup B (RSV B) neutralizing titers (NTs) with RSVpreF in this study's participants to that in Study C3671013 Japanese older adults
Demonstrate that the immune responses to RSVpreF in this study participant are similar to those in Study C3671013 Japanese older adults
Time frame: 1 month after vaccination
GMT of NTs for RSV A and RSV B
Describe the immune responses to RSVpreF with GMT of NTs for RSV A and RSV B before vaccination and at 1 month after vaccination.
Time frame: 1 month after vaccination
Geometric mean fold rise (GMFR) of NTs for RSV A and RSV B
Describe the immune responses to RSVpreF with GMFR of NTs for RSV A and RSV B from before vaccination to 1 month after vaccination.
Time frame: 1 month after vaccination
Seroresponse rate of NTs for RSV A and RSV B
Describe the immune responses to RSVpreF with seroresponse rate of NTs for RSV A and RSV B at 1 month after vaccination. Seroresponse is defined as a postvaccination NT ≥4 times the lower limit of quantitation (LLOQ) if the baseline titer is below the LLOQ; or a ≥
Time frame: 1 month after vaccination
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2026 to primary completion in Aug 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrysvo